Sentences with phrase «drug companies also»

The influence of drug companies also extends to the training that current and future veterinarians receive.

Drug companies also have been busy making sure that lawmakers know how they feel.

Not exact matches

Cramer was also burned on Pfizer's aborted takeover bid for drug company Allergan, which had an overseas taxation rate that would allow the company to pay lower taxes than if it were based in the U.S.

Federal prosecutors, report the Bloomberg writers, «are also investigating relationships between PBMs and large drug companies» and the U.S. Attorney's Office in Manhattan has ordered three makers of insulin to turn over documents regarding those relationships.

It also has partnerships with academic institutions and drug companies like Genentech and Otsuka.

Weston said his family, who also controls Loblaw's parent company, George Weston Ltd. (TSX: WN), has undergone some major changes in the past year, including the $ 12.4 - billion blockbuster acquisition of the Shoppers Drug Mart chain.

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

Drug companies say the law will not only be ineffective, but will also threaten innovation and development.

The men's pill also needs to clear another major hurdle: a pharmaceutical company has to pay to make the drug.

Over in the House of Representatives, Democrats have also been hot on the tail of pharmaceutical companies that have jacked up the prices of some of their drugs, though they've making less headway than their Senate bipartisan counterparts.

He was also briefly dabbled in smuggling opium to China via his American Fur Company ships — even though China banned the drug about two decades earlier.

It is also restricted almost entirely to Africa, which, unfortunately for its victims, makes it a less attractive target for big drug companies than a host of non-fatal diseases (think erectile dysfunction) that are more common in rich countries.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

Sarissa also holds stakes in AbbVie, Biogen and Innoviva, among other drug companies.

Some opponents also pointed to provisions in earlier versions of the bill that could make it easier for drug companies to obscure their financial contributions to hospitals and doctors under the Physician Payments Sunshine Act, which is part of Obamacare.

Daiichi Sankyo's press release comes in the wake not only of Ranbaxy's highly unusual criminal guilty plea and $ 500 million in fines and penalties — the largest ever against a generic - drug maker — but also a lengthy Fortune article that exposed for the first time the depth and extent of the fraud charges leveled at the company and the knowledge of senior company executives.

Sally Susman, a Pfizer executive who oversees the drug company's PAC, is also in the group promising at least $ 100,000.

They also spell out changes to company culture, including prohibiting romances between bosses and their reports and creating clearer guidelines around use of drugs and alcohol.

Google - backed biotech company Calico has also forged a partnership with a Chicago - based biopharmaceutical firm to develop age - defying drugs.

To this end, Calico has also forged a partnership with a Chicago - based biopharmaceutical company called AbbVie, in order to develop drugs that will tackle aging and age - related diseases such as neurodegeneration and cancer.

Her company is best known for jacking up the price of life - saving EpiPen anti-allergy medication, but it also manufactures naloxone, a drug meant to treat opioid over-doses.

And despite the fact that Mylan raised EpiPen prices roughly 30 % in 2015 while prescription volume also grew 7 %, the company's revenue on the drug actually fell slightly, as the other players took even bigger cuts, according to Raffat.

This sort of performance surely pleased investors, but they also have faith that the company will be able to continue to diversify its revenue stream with drugs like chemotherapy treatment Abraxane, which was acquired through Celgene's 2010 takeover of Abraxis.

Allergan would also bolster Pfizer's «innovative» (i.e. brand - name) drug business, which it internally separated from its slower - growing «established» (i.e. generic and non-patented) drug division in 2014, further signaling that it may be planning to split into two different companies altogether.

That's particularly unfortuante for Cerecor seeing as CERC - 501 is the company's lead drug candidate — and the news comes just days after Cerecor announced that a separate experimental depression drug called CERC - 301 had also failed in the clinic.

Importantly, the deal also means that Gilead / Kite rival Novartis (which had its own CAR - T drug approved ahead of Yescarta) and other CAR - T companies won't be able to get in on Sangamo's platform.

Solanezumab, a drug developed by Eli Lilly that also acts on the amyloid hypothesis, failed some key clinical trials, though the company is still testing it in the pre-clinical stages of the disease.

The company has developed an injectable liquid that turns solid when it enters the body to aid in (among other things) drug delivery; it's also invented a polymer - based artificial muscle — similar to Rajagopalan's abandoned PhD project — used in compression wear to counter pain.

While Yervoy brought in $ 960 million in sales in 2013 (an enormous figure for a two - year - old drug with a small patient population), the company currently has more than 35 ongoing clinical trials investigating another drug that disengages the immune system's brakes: the much - awaited nivolumab, which was also from the Medarex portfolio.

When Sarepta Therapeutics nabbed a pioneering approval for a Duchenne muscular dystrophy (DMD) drug last year, it won more than just bragging rights and a controversial FDA approval: the firm also landed a coveted «priority review voucher,» which can either be sold off to another company or used to slash the review period for a future Sarepta treatment.

Bristol's $ 2.4 billion purchase of Medarex — which pharmaceutical analysts routinely cite as one of the best acquisitions in the history of the industry — would give the company not only a new blockbuster but also a leadership position in a burgeoning drug category: immuno - oncology.

Ricks also addressed President Donald Trump's decision to lambast pharmaceutical companies over the price of prescription drugs, in his State of the Union address Tuesday evening.

Her seemingly well - orchestrated announcement of diabetes along with a sponsorship deal with a diabetes drug company came off as insincere to many at the time, especially when they also perceived that the lifestyle her brand promotes could be a contributing cause.

By bringing a drug that's been well - established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny — it will also receive a coveted «priority review voucher» which it can hawk to another firm for tens (or even hundreds) of millions of dollars.

Trump promised to not only roll out competitive bidding for drugs but also pressure companies to manufacture their meds in the U.S.

The California Medical Association, which represents doctors in California, opposes the measure because of that claim, and also because the group said the cancellation of drug purchasing contracts the state already has with pharma companies «would remove many drugs from the Medi - Cal list of pre-approved medicines — creating a new prior authorization hurdle for patients and their physicians.»

The campaign also said that Prop 61 «would invalidate many drug discount agreements the state has negotiated with pharmaceutical companies,» which would increase state prescription costs by tens of millions of dollars each year.

While the companies said they want to lower costs, CVS also makes money on rebates from drug makers and on filling prescriptions through its pharmacies.

But company leadership also maintained that the drug is a «best - in - class anti-inflammatory disease - modifying therapy,» as Chief Executive Officer Stuart Peltz said on the company's earnings call.

While terms like «patent protection» and «public domain» were clearly part of the IPR debate, it also stretched to the cost of drugs and the availability of medicines, encompassing terms like «health advocates» and «pharmaceutical companies.»

Federal investigators are also said to be looking at the issue of drug prices, and several companies, including Valeant Pharmaceuticals International, have said they have received subpoenas.

In addition, the company did a good job protecting its top - selling drug, Remicade, from biosimilar competition while also enjoying strong sales growth for products like Darzalex and Stelara.

The company also has a deep pipeline of nine new drugs, including those that treat ulcerative colitis and multiple sclerosis.

Biotechnology stocks also took a hit as shares of Gilead Sciences Inc dropped 7.8 percent after the company reported a lower quarterly profit on falling sales of its flagship hepatitis C drugs.

Forecasting Sales Revenue Forecasting the sales revenue from each of a biotech company's drugs is probably the most important estimate you can make about future cash flows, but it can also be the most difficult.

The company also announced Q3 revenue that missed expectations, mostly because the 12 % growth of its psoriasis drug Otezla was considered disappointing.

Yep but I think that in Ontario they forbid pharmacy to also own a drug company and thet were discussing the matter in quebec too.

Also in 1956, Searle, a giant drug company, submitted to the Food and Drug Administration its formula for the first birth - control pidrug company, submitted to the Food and Drug Administration its formula for the first birth - control piDrug Administration its formula for the first birth - control pills.

What do you bet that if the same meds that prevent polycystic ovary disease and other maladies didn't also prevent pregnancy, every one of these misogynistic dolts would be all for insurance companies being forced to cover the costs of such drugs?

The presentation also didn't mention that the U.S. Food and Drug Administration told Impossible Foods that the company hadn't demonstrated the safety of heme after it applied to the FDA seeking GRAS (generally recognized as safe) status.